BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16491555)

  • 1. [Why patent-protected drugs' cost efficiency should be compared with generic preparations].
    Berggren F; Lundin D; Ramsberg J
    Lakartidningen; 2006 Jan 25-31; 103(4):223-4. PubMed ID: 16491555
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug costs threaten patent protection.
    Cimons M
    Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
    [No Abstract]   [Full Text] [Related]  

  • 3. Lowering the cost of prescription drugs.
    Jindal B
    J La State Med Soc; 2003; 155(1):51. PubMed ID: 12656276
    [No Abstract]   [Full Text] [Related]  

  • 4. [Discount for only one drug of the same group leads to impaired health care quality].
    Bergström R
    Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
    [No Abstract]   [Full Text] [Related]  

  • 5. Statin utilisation--recognising the role of the invisible hand.
    Minhas R
    Int J Clin Pract; 2007 Jan; 61(1):3-6. PubMed ID: 17229171
    [No Abstract]   [Full Text] [Related]  

  • 6. [The patent legislation in India fails the HIV/AIDS work].
    Holen Ø
    Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2666-7. PubMed ID: 16215618
    [No Abstract]   [Full Text] [Related]  

  • 7. Drugmakers fight for good name. Stakes high, challenges many for providers who seek generic products.
    Becker C
    Mod Healthc; 2001 Aug; 31(35):28-33, 1. PubMed ID: 11550428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focus on the patent cliff to maximize generic savings.
    Cahn L
    Manag Care; 2012 Nov; 21(11):28-32. PubMed ID: 23236715
    [No Abstract]   [Full Text] [Related]  

  • 9. [The patent is "engine" in drug development].
    Bergström R
    Lakartidningen; 2008 Mar 5-11; 105(10):752. PubMed ID: 18422246
    [No Abstract]   [Full Text] [Related]  

  • 10. [The generics reform lowered drug prices].
    Lundin D; Jacob J; Engström A
    Lakartidningen; 2007 Feb 28-Mar 6; 104(9):680-1. PubMed ID: 17393865
    [No Abstract]   [Full Text] [Related]  

  • 11. Long way down--pharmaceutical companies fear falling off 'patent cliff'.
    Sklan A
    Pharm Pat Anal; 2012 Jul; 1(3):240. PubMed ID: 24386667
    [No Abstract]   [Full Text] [Related]  

  • 12. Generic drug companies are the winners.
    Voth AJ
    CMAJ; 1991 Nov; 145(9):1081. PubMed ID: 1751924
    [No Abstract]   [Full Text] [Related]  

  • 13. Generic drugs go to market. Effective, safe and less expensive.
    Mayo Clin Health Lett; 2006 Sep; 24(9):4-5. PubMed ID: 17139760
    [No Abstract]   [Full Text] [Related]  

  • 14. Generic HIV drugs will widen US treatment net.
    Maxmen A
    Nature; 2012 Aug; 488(7411):267. PubMed ID: 22895314
    [No Abstract]   [Full Text] [Related]  

  • 15. Supreme Court rules against drug patent "evergreening".
    Kondro W
    CMAJ; 2006 Dec; 175(12):1508-9. PubMed ID: 17146081
    [No Abstract]   [Full Text] [Related]  

  • 16. Reforming Canada's Access to Medicines Regime.
    Elliott R
    CMAJ; 2007 Jul; 177(3):270-1. PubMed ID: 17664453
    [No Abstract]   [Full Text] [Related]  

  • 17. Handle with care.
    Macilwain C
    Nature; 2006 Apr; 440(7087):990-1. PubMed ID: 16625170
    [No Abstract]   [Full Text] [Related]  

  • 18. [Free trade agreements make the drugs more expensive].
    Jeppsson A
    Lakartidningen; 2009 Nov 18-24; 106(47):3181. PubMed ID: 20082499
    [No Abstract]   [Full Text] [Related]  

  • 19. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 20. Going over the patent cliff.
    Schommer JC
    Minn Med; 2011 Oct; 94(10):42-3. PubMed ID: 23256283
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.